Vaxart Shareholders Reject Say-on-Pay, Two Directors Barely Re-Elected Amid Proxy Fight
VXRT sits 69% above its 52-week low of $0.305.
Summary
Vaxart shareholders rejected the company's executive pay plan and two directors barely survived re-election, highlighting governance tensions following a proxy contest.
Key Events · Corporate Governance and Compliance · VXRT
-
Say-on-Pay Rejected
Shareholders voted 51.8 million against vs. 46.0 million for the advisory compensation proposal, a clear rejection of executive pay practices.
-
Two Directors Narrowly Elected
Elaine J. Heron received 51.4% support (51.4M for, 48.7M withheld) and Steven Lo received 50.2% (50.3M for, 49.8M withheld), indicating substantial shareholder opposition.
-
Proxy Contest Backdrop
The vote follows a contested proxy season where activist group 'Concerned Vaxart Stockholders' sought to replace three directors, citing mismanagement and dilution.
-
Auditor Ratified
WithumSmith+Brown, PC was ratified as independent auditor with 80.4M votes for, a routine approval.
Analysis · VXRT · Life Sciences
Deep shareholder discontent surfaced at Vaxart's annual meeting. The non-binding say-on-pay vote failed with 51.8 million votes against, a clear rebuke of executive compensation. Directors Elaine J. Heron and Steven Lo each received less than 55% support, signaling significant opposition — likely tied to the ongoing proxy contest by activist shareholders seeking board change. While all six directors were elected, the narrow margins for two incumbents and the compensation rejection add pressure on the board to address governance concerns. This comes just weeks after a heated proxy battle where activists criticized mismanagement and significant dilution.
At the time of this filing, VXRT was trading at $0.52 on OTC in the Life Sciences sector, with a market capitalization of approximately $124.7M. The 52-week trading range was $0.31 to $0.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.